Obama K, Tara M, Sao H, Taji H, Morishima Y, Mougi H, Maruyama Y, Osame M
Internal Medicine, Kagoshima City Hospital, Kagoshima City, Japan.
Int J Hematol. 1999 Apr;69(3):203-5.
We performed allogenic bone marrow transplantation (BMT) in two adult T-cell leukemia (ATL) patients with HLA-identical siblings as donors. One patient, with acute ATL, relapsed 3 months after BMT. The other, with chronic ATL, has become free of disease over 18 months after the BMT from his human T-cell lymphotropic virus type 1 (HTLV-1)-negative sibling, and we were unable to detect HTLV-1 in the patient's peripheral blood. Based on our results and those of others, although there have been limited numbers of patients, BMT may represent the only potentially curative treatment for ATL, and the presence of graft-vs.-host disease tends to be related to good results, which suggests the possibility that graft-vs.-leukemia effects may play an important role in allogenic BMT for ATL.
我们对两名成年T细胞白血病（ATL）患者进行了同种异体骨髓移植（BMT），供体为人类白细胞抗原（HLA）相同的同胞。一名急性ATL患者在BMT后3个月复发。另一名慢性ATL患者，在接受来自其1型人类嗜T淋巴细胞病毒（HTLV-1）阴性同胞的BMT后18个月以上未出现疾病，且我们在该患者外周血中未检测到HTLV-1。根据我们的结果以及其他人的结果，尽管患者数量有限，但BMT可能是ATL唯一潜在的治愈性治疗方法，且移植物抗宿主病的存在往往与良好的治疗效果相关，这表明移植物抗白血病效应可能在ATL的同种异体BMT中发挥重要作用。
Zotero 插件